Falk Gastro Info 2/2017

Video

Video course abdominal ultrasound

Examination of the mediastinum: Prevascular region

Author: Prof. Dr. Christoph F. Dietrich, Caritas Krankenhaus Bad Mergentheim.

Please switch on your loudspeakers!

Link to Falk Mediacenter

Latest research in brief:

Bowel

Text:

Bhattacharya A et al, Inflamm Bowel Dis. 2016;22(11):2665–71

Prognosis of „silent Crohn’s disease“: Patients with elevated CRP concentrations despite being in clinical remission have an approx. 7-fold increased risk to develop significant bowel damage over the ensuing years.

Link to text

Text:

Dulai PS et al, BMJ. 2016;355:i6188

Chemoprevention of metachronous colorectal neoplasia: Network meta-analysis reveals that non-Aspirin NSAIDs are the most effective agent, whereas low-dose aspirin has the most favorable risk:benefit profile.

Link to text

Text:

Aveyard P et al, Lancet. 2016;388(10059):2492–500

creening and brief intervention for obesity in primary care: A behaviorally-informed, very brief physician-delivered opportunistic intervention about the risks of obesity is acceptable to patients and effective to reduce weight.

Link to text

Liver Biliary Tracts

Text:

Dahlqvist G et al,Hepatology. 2017;65(1):152–63

Primary biliary cholangitis (PBC): Nearly half of newly detected antimitochondrial antibodies (AMAs) in clinical practice does not lead to diagnosis of PBC. Only 1 in 6 patients with AMAs and normal alkaline phosphatase will develop PBC after 5 years; however, these patients display an increased mortality, irrespective of PBC development.

Link to text

Text:

Bureau C et al, Gastroenterology. 2017;152(1):157–63

Liver cirrhosis: In a recent prospective, randomized, controlled trial, a covered transjugular intrahepatic portosystemic shunt (TIPS) increased transplant-free 1 year survival in patients with recurrent ascites compared to repeated large-volume paracenteses and albumin.

Link to text

Text:

Bruix J et al, Lancet. 2016;389(10064):56–66

Hepatocellular carcinoma (HCC): Regorafenib provides survival benefit in HCC patients progressing on sorafenib treatment. In the randomized, double-blind, placebo-controlled phase 3 trial RESORCE, median survival was 10.6 months with regorafenib versus 7.8 months with placebo.

Link to text

Oesophagus Stomach Duodenum

Text:

Tran-Duy A et al, Clin Gastroenterol Hepatol. 2016;14(12):1706–19.e5

Complications of proton pump inhibitor (PPI) therapy: Long term PPI use is associated with increased risk of fundic gland polyps and gastric cancer.

Link to text

Text:

Chen Q et al, Am J Gastroenterol. 2016;111(12):1736–42

Rescue therapy for Helicobacter pylori: A novel bismuth-containing quadruple therapy with metronidazole and amoxicillin is non-inferior to conventional bismuth-containing quadruple therapy with tetracyclin and characterized by superior patient safety and compliance.

Link to text

Text:

Stoven SA et al, Clin Gastroenterol Hepatol. 2016;14(11):1582–8

Endoscopic diagnosis of celiac disease: In a low pretest probability cohort, separate sampling of the duodenal bulb had only minimal impact on celiac disease detection.

Link to text

Pancreas

Text:

Sharaiha RZ et al, Clin Gastroenterol Hepatol. 2016;14(12):1797–803

Endoscopic therapy of pancreatic walled off necrosis: A retrospective multicenter study with 124 patients confirms that lumen-apposing metall stents are safe and effective.

Link to text

International Symposia and Workshops

Symposium 206

From the New and Complex Concepts to the Real Patient: Science and Clinic in IBD

March 31 – April 1, 2017, Madrid, Spain

Meliá Castilla Hotel, Calle del Capitán Haya, 43, 28020 Madrid, Spain

Program

Registration

Online registration

Symposium 207

Mucosal Microbiome and Mucosal or Systemic Dysfunction: Mechanisms, Clinical Manifestations and Interventions

May 19 – 20, 2017, Brisbane, Australia